Therapeutics Companies in France

"Innovative medicine for everyone, everywhere" Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia operates in the diabetes and metabolic disease field. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : http://offres.adocia.com/en

To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial. Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages. By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.). For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions. CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.

Ludocare is to create ways to provide assistance to patients and their families to improve their abilities, autonomy, and quality of life.

CardioRenal uses the advanced technologies to develop digital therapeutic solutions.

PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with our leading expertise in GMP NGS-based biosafety testing and characterization services. As innovator companies continue to bring exciting novel therapies to market, there is a critical need for alternative biosafety and characterization strategies. This is especially the case for life-changing cell and gene therapies, as well as novel viral vaccines. Classical testing approaches, such as cell based assays, are often challenging to implement due to high volume requirements, as well as compatibility issues. Biosafety testing and characterization are key regulatory requirements for the release of biologic therapies. Therefore, alternative methods which can address these issues are of intense interest. There is also a drive from across industry and regulators to reduce, and eventually eliminate the use of animal models used in biosafety testing. The genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays From our origins within the Institut Pasteur, PathoQuest is leading the way in expertise for the provision of GMP NGS based biosafety testing. Our expertise is underlined with over 20 peer reviewed publications on NGS applications in biosafety testing; as well as active participation in industry groups such as PDA, ADVTIG, CAACB and EFPIA. PathoQuest are committed to bringing this game-changing genomic approach to biopharmaceutical developers and manufacturers. PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA); and have provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally. Why not get in touch to see how we can help you with your biosafety testing strategy?

Reflexologie Paris 17 offers holistic massages and reflexology for relaxation, stress relief, and natural healing in a peaceful Paris center.